Long-term disease stabilization by docetaxel plus estramustine for castration-resistant prostate cancer : Report of a case - Abstract

The Department of Urology, Shiga University of Medical Science, Japan.

 

Chemotherapy with docetaxcel (DTX) plus estramustine (EMP) for castration-resistant prostate cancer (CRPC) was started 30 months after the patient, a 65-year-old man, was diagnosed as having advanced prostate cancer cT3aN1M1 (OSS) with an initial PSA of 490 ng/ml. Prostate biopsy specimens revealed moderately differentiated adenocarcinoma, Gleason's sum 4+5. He was treated with DTX 30 mg/m2 on day 2 and oral EMP 560 mg/day days 1-3 weekly for 3 out of 4 weeks. PSA at start of DTX plus EMP was 81.7 ng/ml, and that after 59 months was 66.6 ng/ml. No objective change in computed tomography and bone scan were observed. He also had no cancer-related symptoms and activity of daily life was good. Chemotherapy was interrupted twice because of pleural effusion and dyspnea by DTX, at 3 and 4 months, respectively, long-term disease stabilization was obtained by this treatment. Other adverse events including interstitial pneumonia, cardiovascular disorders and myelosuppression were not observed. He was maintained on the same chemotherapy. DTX plus EMP chemotherapy is an effective treatment for CRPC patients. Continuing this therapy it is important to survey and control adverse events caused by DTX and EMP carefully.

Article in Japanese.

Written by:
Kageyama S, Iwaki H, Masuda Y, Yoshida T, Narita M, Okada Y.   Are you the author?

Reference: Hinyokika Kiyo. 2011 Apr;57(4):203-7.

PubMed Abstract
PMID: 21646852

UroToday.com Prostate Cancer Section

 

 

email news signup